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Memory T cells are necessary for protective immunity against invading pathogens,
especially under conditions of immunosuppression. However, their presence also threat-
ens transplant survival, making transplantation a great challenge. Significant progress
has been achieved in recent years in advancing our understanding of the role that
memory T cells play in transplantation. This review focuses on the latest advances in
our understanding of the involvement of memory T cells in graft rejection and transplant
tolerance and discusses potential strategies for targeting memory T cells in order to
minimize allograft rejection and optimize clinical outcomes.
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Introduction
Adaptive immune responses depend on the ability to recognize and eliminate recurrent pathogens,
resulting in the generation of memory lymphocytes. The capacity of memory T cells to rapidly
mobilize and initiate a potent recall response enhances protective immunity against previously
encountered pathogens. However, the characteristics of memory T cells, with their lowered acti-
vation thresholds and lower susceptibility to conventional immunosuppressive agents, also makes
them a significant obstacle to successful transplantation (1).
In the context of transplantation, three independentmechanisms for the generation of alloreactive
memory T cells have been described. First, since memory T cells can be generated directly during
primary immune responses, alloantigenic stimulation of naïve T cells serves as the most direct
source of alloreactive memory T cells (2). Second, alloreactive memory T cells can also be generated
through homeostatic proliferation, a spontaneous process that occurs in response to transient
lymphopenia and induces the proliferation and differentiation of naïve T cells into memory cells; in
transplantation, severe lymphopenia is often seen after T-cell depletion therapy (3). Third, memory
T cells generated in response to infectious or environmental antigens have the potential to cross-react
with donor allogeneic MHC molecules (4), creating a situation known as heterologous immunity.
In recent years, a broader perspective has been established with regard to our understanding of the
basic biology of memory T cells. Also, new approaches for modulating memory T cells have been
designed and tested in various models, including transplantation. In this review, we mainly discuss
the role of memory T cells in transplantation and explore the development of therapeutic strategies
that can directly target memory T cells.
The Role of Memory T Cells in Transplantation
In contrast to naïve T cells, memory T cells have lower activation thresholds and are less dependent
on costimulation signals (5), are more resistant to regulation by regulatory T cells (Treg) (6), and
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are less susceptible to conventional immunosuppressive agents
(1). These features make memory T cells a significant obstacle
to successful transplantation. However, the exact mechanisms
involved remain unclear. In the pursuit of innovative and effective
strategies to inhibit or deplete memory T cells and improve the
clinical outcomes, a profound and comprehensive understand-
ing of its role in transplantation is urgently required. Therefore,
studies based upon animal models and clinical observations have
therefore been established to directly or indirectly demonstrate the
impact of memory T cells on transplantation and to elucidate the
relevant mechanisms.
One Chief Culprit for Rejection
In addition to their role in protective immunity, memory T cells
also take part in mediating transplant rejection (7). It is well
understood that donor-specific memory T cells mediate the
so-called second-set rejection that is rather difficult to block
or inhibit (8, 9). In animal models, memory T cells alone are
sufficient to trigger rejection, during which they are among the
first cell types infiltrating the grafts (10). In recent observations
from clinical practice, the expansion of memory CD8+ T cells
and memory CD4+ T cells has been found to be associated with
acute cellular and antibody-mediated rejection, respectively, in
liver transplantation (11, 12), and these findings are consistent
with reported experimental outcomes.
In the absence of direct stimulation by alloantigen, memory
T cells generated through either homeostatic proliferation or het-
erologous immunity seem to have the same ability to mediate
transplant rejection. It has been demonstrated that the memory T
cells generated via homeostatic proliferation act as potent effector
cells in the rejection of heart and skin allografts (5). Likewise,
heterologous immunity may also lead to the generation of allore-
activememoryT cells (13). Functional heterogeneity of the human
T-cell response induced by pathogens and vaccines has recently
been described (14). Infection of B6 mice with parasitic or viral
antigens, for instance, has been found to cause the generation of
alloreactive memory T cells. As a result, heart grafts transplanted
into these pathogen-recognizing mice demonstrate an accelerated
rejection (15). It has also been reported that naïve untreated adult
laboratory mice possess a repertoire of endogenous memory T
cells that are naturally generated by environmental exposure (16).
Endogenous memory T cells are not previously primed to donor
antigens; however, a proportion of the endogenousmemory T-cell
repertoire in naïve mice is reactive with donor class I MHC
molecules, and these T cells are rapidly detected and infiltrate
into cardiac allografts within hours of reperfusion (17). In other
selected models, memory T cells have been shown to be pivotal
mediators of chronic allograft rejection, implying that memory
T cells and chronic rejection may also be tightly associated (18,
19). Therefore, despite the different mechanisms by which they
are generated, memory T cells are capable of mediating rejection.
The cognate interactions between memory helper T cells and
B cells are also important for the development of allograft rejec-
tion. On the one hand, it has been reported that donor-reactive
memory CD4+ T cells can provide CD40-independent help to
B cells and induce high levels of alloantibodies that contribute
to heart allograft rejection in mice (20). The CD40-independent
help delivered by memory CD4+ T cells in alloreactive immune
responses is mainly mediated by B cell activating factor (BAFF)
and a proliferation-inducing ligand (APRIL), as targeting the
BAFF cytokine network has been reported to be able to inhibit
both humoral and cellular immune responses induced by mem-
ory CD4+ T cells (21). Additionally, IFN-γ secreted by pre-
existing memory helper cells has been found to be required for
the CD40-independent alloantibody responses, which determines
both isotype and specificity of donor-reactive alloantibodies and
can thus affect allograft (22). On the other hand, B cells can
also provide help for T cells via multiple mechanisms promot-
ing T-cell proliferation, differentiation, and survival to generate
memory T cells. Experimental evidence has shown that activated
T cells cotransferred with B cells give rise to more memory T cells
than those transferred without B cells and upon recall, mediated
accelerated rejection of skin allografts in mice (23). Therefore,
inhibiting memory T/B cells interactions could possibly prevent
not only alloantibody production but also generation of long-lived
memory T cells, which may improve allograft survival.
Turnoff: Tolerance-Inducing or Not?
Another important concern is the correlation between memory
T cells and tolerance induction in transplantation.Memory T cells
have been found to be highly resistant to tolerance induction,
and tolerizing therapies that are effective in inducing allograft
tolerance in naïve animals often fail to do so in memory-rich
animals (24). A higher frequency ofmemory T cells in recipients is
associated with a worse transplant outcome and poorer tolerance
induction under conventional immunosuppression (25).
Memory T cells are distinguished by their reduced requirement
for both TCR stimulation and costimulatory signals for recall
responses. Showing differences in the expression of adhesion
molecules (such as LFA-1, VLA-4, and CD44), cytokine receptors
(such as CD122 and IL-15Rα), and apoptosis involving molecules
of the Bcl-2 and caspase-3 families when compared to naïve
T cells, donor-reactive memory T cells are relatively refractory
to any blockade of conventional costimulatory pathways (26–
29). In a seminal study, although blockade of costimulation by
CD28 and CD154 effectively inhibited graft rejection in naïve
recipients, animals that had previously been infected with viruses
were found to be refractory to the tolerance-inducing effects of
this costimulation blockade; while this study focused primarily
on the CD8+ memory T-cell barrier, it is clear that both CD4+
and CD8+ donor-specific memory cells can constitute a bar-
rier to costimulation blockade-induced tolerance (30). A study
examining the efficacy of an approach combining costimulatory
blockade and bone marrow or donor-specific transfusion (DST)
to induce tolerance in non-human primate renal transplantation
showed that higher pre-transplant precursor frequencies of donor-
reactive memory T cells were correlated with a failure of tolerance
induction and acute rejection of the grafts, whereas low pre-
transplant frequencies of donor-reactivememoryT cells predicted
successful tolerance induction and long-term renal survival (31).
Memory T cells have also been shown to exhibit increased
resistance to regulation by Treg. In a murine model, transferred
CD4+CD25+ cells effectively inhibited the rejection mediated by
naïve but not by memory CD4+ T cells (32). Similarly, Treg were
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found to be unable to regulate CD8+ alloreactive T-cell responses,
a finding that was true for both naive Treg and alloantigen-primed
Treg, suggesting that strategies to enhance the frequency and/or
activation of alloantigen-specific Treg are unlikely to be effective
against donor-reactive memory T cells (33). However, another
report has suggested that the stimulation of human T cells in vitro
with TLR-stimulated plasmacytoid dendritic cells results in the
generation of CD8+FoxP3+LAG-3+CTLA-4+ Treg, which can
inhibit alloreactive memory T-cell responses (34, 35). It has also
been reported that human CD45RA FoxP3hi memory-type Treg
use a different T-cell receptor (TCR) repertoire from conventional
T cells and play an important role in controlling early immune
activation (36). Thus, such regulatory effects might be of clinical
importance in the pursuit of a desirable level of tolerance.
Current and Potential Memory
T Cell-Directed Intervention Therapies
If the negative impact of memory T cells on transplantation and
their distinct hindrance of tolerance induction are taken into
account, strategies to target memory T cells may offer a solu-
tion to improve transplant outcomes. The pursuit of memory
T cell-directed therapies in transplantation has arisen from the
observation that standard immunosuppressive agents often have
undesirable effects on memory T cells. Nevertheless, studies in
several experimental models have suggested that targeting the
infiltration, proliferation, activation, and the intrinsic apoptosis
pathway of memory T cells and the blocking of memory T/B cells
interactions may be promising therapeutic approaches.
Blocking the Infiltration of Memory T Cells
After organ transplantation, the alloreactive memory T cells first
infiltrate the grafts, then proliferate andmediate significant injury.
Therefore, inhibition of their initial entry into the graft may
improve allograft survival. There have been numerous attempts
to control memory T-cell infiltration in transplant models. For
example, the administration of FTY720, the sphingosine-1 phos-
phate receptor agonist, has been found to lead to a quarantine
of donor-specific memory CD4+ T cells in the peripheral lymph
nodes and to postpone heart allograft rejection in mice (37). In
this situation, the administration of FTY720 prevents the migra-
tion of lymphocytes from thymus and peripheral lymphoid tis-
sues, sequesters T cells in the lymphnodes, and inhibits them from
infiltrating the grafts. However, this sequestration does not affect
the ability of donor antigen-reactive CD4+ T cells to facilitate
the helper signals needed to stimulate a donor-specific antibody
response, which plays a vital role in the graft loss in these FTY720-
treated recipients.
Other studies have also demonstrated that the disruption of
adhesion molecules, e.g., leukocyte integrins such as LFA-1 and
VLA-4, is effective in preventing the infiltration of memory T
cells into grafts (38, 39). Anti-LFA-1 or anti-VLA-4 monoclonal
antibodies can attenuate donor-reactive memory recall responses
and reduce T-cell trafficking into allografts in mouse models,
resulting in a prolongation of allograft survival (40). However,
a preclinical test of the anti-LFA-1 agent Efalizumab in primate
renal transplantation suggested that this agent evokes a higher rate
of EBV-associated malignancy despite the promising outcomes
produced for the grafts (40, 41). Taken together, these successful
treatments in animalmodels, though not currently available in the
clinic, suggest that targeting trafficking molecules on memory T
cells may be a valid approach, but further investigation is urgently
needed to provide a full evaluation of its clinical validity and
potential side effects.
Suppressing the Proliferation of Memory T Cells
Another potential therapeutic strategy is targeting the prolifera-
tion of memory T cells induced by cytokine and TCR signaling.
Janus kinase-3 (JAK-3), the downstream receptor of the common
γ chain, binds amagnitude of cytokines, including IL-2, IL-7, IL-9,
IL-15, and IL-21 (42). These cytokines have been shown to play
pivotal roles in the generation, maintenance, and proliferation
of memory T cells. Tofacitinib (CP-690550), a highly selective
and potent JAK-3 inhibitor, has been shown to prevent allograft
rejection in both rodent and non-human primatemodels andmay
offer a novel means of targeting memory T cells without TCR
inhibition (43).
Cell proliferation and survival signaling may also be induced
through the TCR pathway. Nuclear factor-κB (NF-κB), a protein
complex that regulatesDNA transcription, plays an important role
in the TCR pathway (44). The NF-κB blocker 15-deoxyspergualin
can block the activation of donor-specific memory CD8+ T
cells and has been shown to induce skin allograft survival in a
mouse model in combination with costimulatory blockade (45).
The inhibition of NF-κB also suppresses the proliferation of
rapamycin-resistant memory T cells in non-human primates (46).
Inhibiting the Activation of Memory T Cells
An increasing amount of evidence has shown that conventional
blockade of costimulation has only a minimal effect on memory
T cells. Several studies have suggested that memory T cells use
alternative, unique costimulatory pathways for activation and
effector activity. On CD8+ T cells, it has been shown that the
engagement of 4-1BB (CD137) by its ligand provides both CD28-
dependent and CD28-independent signals that lead to cytokine
production, cell proliferation, augmented cytotoxic effector activ-
ity, and enhanced cell survival (47). In mouse models, blockade
of the 4-1BB costimulatory pathway has been shown to be valid
in prolonging the survival of intestinal, skin, and heart allografts
(48, 49). Another costimulatory pathway that might account for
the recall of memory T cells is the OX40/OX40L pathway (50).
A deficiency in or blockade of OX40 has been shown to lead
to an impairment of memory CD4+ T cell formation and to
prolong the survival of heart and skin allografts in recipients. Anti-
OX40Lmonoclonal antibody prolongs the secondary cardiac allo-
graft survival on the basis of CD40/CD40L and LFA-1/ICAM-1
blockade, with the anti-OX40L mAb impairing the generation of
memory T cells and up-regulating IL-10-producing Tregs, thereby
inhibiting T-cell function (51).
Depleting Memory T Cells
In addition to the strategies mentioned above, the most common
therapeutic option for induction in transplantation is the admin-
istration of polyclonal antithymocyte globulin (ATG), which is
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produced in response to target thymocytes or T-cell lines (52,
53). Although ATG can effectively deplete alloreactive T cells,
lymphopenia will induce compensatory proliferation that para-
doxically supports memory T cells, favoring graft rejection and
making it difficult to achieve or sustain operational tolerance
of the graft (54, 55). However, several studies have shown that
ATG may also play an important role in human Treg survival
and expansion both in vitro and in vivo (56, 57). An increased
ratio of Treg/T effector cells during ATG-induced homeostatic
proliferation has been observed in rat kidney transplantation (58).
Although memory T cells are much more resistant to deple-
tion than are naïve T cells, Tregs proliferate to a significantly
higher extent than do effector T cells, which suggests a biological
preference of ATG for regulation rather than for promoting an
effector immune function. In mice, it has been reported that pre-
transplant administration of ATG results in increased efficacy in
controlling donor-reactive memory T cells when compared to
its peri-transplant administration (59). The application of ATG
pre-transplantation results in a greater inhibition of pre-existing
donor-reactive memory T-cell responses and a slower recovery
of memory T cell counts than does peri-transplant treatment,
making ATG-mediated depletion more efficient in prolonging
allograft survival (59).
Some fundamental studies of the role of apoptosis in memory
T cells have prompted us to target the apoptotic pathway to
achieve functionally relevant depletion of memory T cells (58,
60). Regulation of the intrinsic apoptotic pathway by both pro-
and antiapoptotic factors of the Bcl-2 family is critically impor-
tant for the selection of T-cell clones for memory generation
and for the maintenance of memory T cells. ABT-737, a small-
molecule inhibitor of Bcl-2/Bcl-XL, efficiently induces apoptosis
in alloreactive memory T cells in vitro and in vivo and prolongs
skin graft survival in sensitized mouse recipients (26). Memory
T-cell reduction produced by Bcl-2 inhibition seems to represent
an important advance in the field of transplantation, which may
benefit HLA-presensitized transplantation as well as tolerance
induction.
Blocking Memory T/B Cells Interactions
As mentioned above, blocking interactions between memory
T and B cells in transplantation may prevent not only alloanti-
body formation but also generation of long-lived memory T cells
improving allograft survival. The short-term neutralization of
BAFF alone or BAFF plus APRIL synergized with anti-CD154
monoclonal antibody was reported to prolong heart allograft
survival in recipient mice containing donor-reactive memory
CD4+ T cells, indicating that reagents neutralizing BAFF and
APRIL might be used to enhance the efficacy of CD40/CD154
costimulatory blockade and improve allograft survival in T-cell-
sensitized recipients (21). Another recent study reported that IFN-
γ neutralization via blocking anti-IFN-γ antibody could prevent
memory CD4+ T cells from providing CD40-independent help
to B cells and thus improve allograft survival, which might be
valuable for identifying transplant patients at risk for generation of
de novo alloantibodies and for preventing alloantibody production
in T-cell-sensitized recipients (22).
Conclusion
Despite their role in protective immunity against invading
pathogens, the presence of memory T cells also threatens trans-
plant survival. The unique characteristics of memory T cells in
protective immunity against recurrent pathogens also make them
formidable barriers to desired tolerance and successful trans-
plantation. Studies in experimental models have suggested that
targeting the infiltration, proliferation, activation, and intrinsic
apoptotic pathway of memory T cells may be promising thera-
peutic approaches. However, with any therapy designed to inhibit
memory T-cell recall responses, there is an inherent risk of impair-
ing pathogen-specific protective immune responses. Therefore,
the benefits in terms of graft survival obtained by attenuating
memory T-cell responses must be carefully weighed against the
cost of compromised protective immunity, the risk of infection
of the host, and the potential for the development of malignancy.
Recent evidence, however, has shown fundamental differences in
the recall responses to pathogens and allografts of memory T cells
that may offer a therapeutic window in which “detrimental” graft-
specific recall responses can be attenuated, while “beneficial”
pathogen-derived responses remain unaffected.
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